March 16, 2026 4:42pm

Helps shove the cell and gene therapy sector back to reality

More is needed to reflect past deficiencies and current less than adequate valuations

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening; Do I see green sprouts? … https://www.regmedinvestors.com/articles/14349

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt, barely fulfills the need of a PPM raise … https://www.regmedinvestors.com/articles/13812

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Monday: The Dow closed UP +387.94 points or +0.83%, the S&P closed UP +67.19 points or +1.01% while the Nasdaq closed UP +268.819 points or +1.22%

  • Theme of the session: oil pricing is falling

Friday’s (my) 40-company covered sector’s advance/decline line opened positive with 34 incliners, 3 decliners and 3 flats, ending with a positive close of 27 incliner, 10 decliners and 3 flats

  • The Russell 2000 index paced the 3 major averages by about 0.94% in trading

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Monday’s bounce was overdue after weeks of pressure amid the Iran war. However, it was not accompanied by strong volume, to show conviction behind the move

The CBOE Fear (VIX) index, Monday 12.72, Friday’s 27.19, Thursday’s 27.27, Wednesday’s 24.31, Tuesday’s 25.46, and last Monday’s 25.54

Metrics: Monday …

  • The RUT was up +23.24 points or +0.94%,
  • The XLV was up +1.22 points or +0.81%,
  • The NBI was up +58.72 points or +1.03%;
  • The XBI was up +2.08 points or +1.71%
  • The IWM was up +2.33 or +0.94%;
  • The IBB was up +1.63 points or +0.98%,
  • The VIX was down -3.47 points or -12.75% at to 23.72

 

Q1/26 – March – 4 positive and 7 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Monday Closing UP (10 of 27) 

  • Alnylam Pharmaceuticals (ALNY +$5.50 after Friday’s -$3.82),
  • Arrowhead Pharmaceuticals (ARWR +$2.322 after Friday’s +$0.04),
  • Ionis Pharmaceuticals (IONS +$1.15 after Friday’s -$1.15),
  • Moderna (MRNA +$0.75 after Friday’s -$0.83),
  • BioLife Solutions (BLFS +$0.72 after Friday’s +$0.21),
  • Intellia Therapeutics (NTLA +$0.62),
  • AxoGen (AXGN +$0.50 after Friday’s +$0.58),
  • Ultragenyx Pharmaceuticals (RARE +$0.48),
  • uniQure NV (QURE +$0.41),
  • Beam Therapeutics (BEAM +$0.33),

Flat (3)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN) – Ponzi Scheme!
  • Precigen (PGEN)

Monday’s Closing DOWN (10 of 10): 

  • Vertex (VRTX -$3.24 after Friday’s -$8.79),
  • BioNTech (BNTX -$0.65 after Friday’s +$1.09),
  • Wave Life Sciences (WVE -$0.61),
  • Lenz Therapeutics (LENZ -$0.41 after Friday’s +$0.33),
  • CRISPR Therapeutics (CRSP -$0.33),
  • Vericel (VCEL -$0.24 after Friday’s +$0.42),
  • Voyager Therapeutics (VYGR -$0.135),
  • Sangamo Therapeutics (SGMO -$0.0176)
  • Caribou Biosciences (CRBU -$0.01),
  • Fate Therapeutics (FATE -$0.01),

 

The Bottom Line: More of the … WHY

US stocks climbed on Monday …

  • Weighing the likely impact of surging oil prices on the Fed's interest rate path hoping for signs of easing in the Strait of Hormuz supply disruption.

Is it just this easy … to explain?

  • Fundamentals have taken a hit; earnings remain a second story, corporate balance sheets are solid with a few stretched.

As Fed officials gather for their 2-day policy meeting this week, the oil shock from the Iran war could deepen divisions with the central bank over the path forward on interest rates.

Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)
  • Thursday – 3/5 – Regenxbio (RGNX), Compass therapeutics (CMPX)
  • Thursday – 3/12 – Capricor Therapeutics (CAPR)
  • Monday – 3/16 – Agenus (AGEN)
  • Wednesday – 3/25 – Precigen (PGEN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 3rd week

  • 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats

March – 2nd week

  • 3/13 – Friday closed negative with 11 incliner, 24 decliners and 5 flats
  • 3/12 – Thursday closed negative with 1 incliner, 36 decliners and 3 flats
  • 3/11 - Wednesday closed negative with 11 incliners, 26 decliners and 2 flats
  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Monday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS)
  • Friday: IQIA Holdings (IQV), BioNTech (BNTX) and AxoGen (AXGN)
  • Thursday: Voyager Therapeutics (VYGR)
  • Wednesday: BioNTech (BNTX), AxoGen (AXGN) and Moderna (MRNA)
  • Tuesday: Vertex (VRTX), Capricor Therapeutics (CAPR) and Dyne Therapeutics (DYN)
  • Last Monday: Vertex (VRTX), IQIA Holdings (IQV) and UniQure NV (QURE)

The worst three (3) in the session: Losers

  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and Wave Life Sciences (WVE)
  • Friday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Capricor Therapeutics (CAPR)
  • Thursday: Vertex (VRTX), IQIA Holdings (IQV) and Alnylam Pharmaceuticals (ALNY)
  • Wednesday: Vertex (VRTX), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: BioNTech (BNTX), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Last Monday: Mesoblast (MESO) and Compass Therapeutics (CMPX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.